---
title: "PTC Therapeutics, Inc.  ( PTCT )  Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - PTC Therapeutics  ( NASDAQ:PTCT ) "
description: "NEW YORK, July 03, 2024 ( GLOBE NEWSWIRE ) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of PTC Therapeutics, Inc. ( \"PTC\" or "
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/207923546.md"
published_at: "2024-07-03T20:41:10.000Z"
---

# PTC Therapeutics, Inc.  ( PTCT )  Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - PTC Therapeutics  ( NASDAQ:PTCT ) 

> NEW YORK, July 03, 2024 ( GLOBE NEWSWIRE ) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of PTC Therapeutics, Inc. ( "PTC" or "the Company" ) PTCT. Investors who purchased PTC securities are encouraged to obtain additional ...

NEW YORK, July 03, 2024 ( GLOBE NEWSWIRE ) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of PTC Therapeutics, Inc. ( "PTC" or "the Company" ) PTCT. Investors who purchased PTC securities are encouraged to obtain additional ...

### Related Stocks

- [PTCT.US - PTC Therap](https://longbridge.com/en/quote/PTCT.US.md)
- [PTC.US - PTC](https://longbridge.com/en/quote/PTC.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| PTC Therap｜10-K：2025 财年营收 17.31 亿美元不及预期 |  | [Link](https://longbridge.com/en/news/276382414.md) |
| PTC Therap｜8-K：2025 财年 Q4 营收 1.65 亿美元不及预期 |  | [Link](https://longbridge.com/en/news/276378877.md) |
| 对 PTC 的平衡展望：Sephience 驱动的增长被杜氏肌营养不良的阻力所抵消，而未建模的 Vatiquinone 潜在上行则支持维持持有评级 | TD Cowen 的 Joseph Thome 对 PTC Therapeutics 维持持有评级，目标价为 75 美元。他提到 Sephience 的早期市场接受度强劲，以及 2026 年 7 亿至 8 亿美元的可信收入展望，但同时面临杜 | [Link](https://longbridge.com/en/news/276406330.md) |
| PTC 公司（PTC）通过与 SPG 的新 FlexPLM 合作如何塑造其智能 PLM 投资故事 | PTC 宣布，SPG 公司选择其 FlexPLM 解决方案以现代化产品生命周期运营，提升数据准确性和协作能力。这一胜利支持了 PTC 对智能产品生命周期的愿景，并与其投资叙述相一致，预计到 2028 年收入将达到 33 亿美元。尽管有积极的 | [Link](https://longbridge.com/en/news/276294946.md) |
| PTC Therapeutics 的盈利前景 | PTC Therapeutics（纳斯达克代码：PTCT）定于 2026 年 2 月 19 日发布季度财报，分析师预计每股收益（EPS）为-0.33 美元。投资者对积极的指引公告抱有希望。该公司此前超出每股收益预期 1.34 美元，导致股价 | [Link](https://longbridge.com/en/news/276258138.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
